We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vircell Announces Immediate Release of COVID-19 Research Kit

By LabMedica International staff writers
Posted on 05 Mar 2020
Print article
Image: The Vircell COVID-19 detection kit (Photo courtesy of Vircell)
Image: The Vircell COVID-19 detection kit (Photo courtesy of Vircell)
An all-out R&D program carried out by the biotechnology company Vircell (Granada, Spain) has resulted in a PCR-based test for the detection of COVID-19.

A novel coronavirus of zoonotic origin, the 2019-nCoV virus (the causative agent of COVID-19 disease) was recently identified in patients with acute respiratory disease. This virus is genetically similar to SARS coronavirus and bat SARS-like coronaviruses. The outbreak was initially detected in Wuhan, a major city in China, but has subsequently been detected in other provinces of China as well as in major outbreaks in several other countries in Asia (South Korea, Thailand, Japan) and Europe (Italy). At this time nearly 80,000 cases of the disease have been confirmed with close to 3,000 fatalities.

Signs of infection are highly non-specific and these include respiratory symptoms, fever, cough, dyspnea, and viral pneumonia. Currently, experts estimate that only a small percentage of coronavirus cases have actually been diagnosed clinically. Therefore, diagnostic tests specific for this infection are urgently needed for confirming suspected cases, screening patients, and conducting virus surveillance.

In response to the potential pandemic spread of the virus, Vircell rapidly developed a product for detection of COVID-19 that is available right now for research use.

The new product generates fast and reliable results in 90 minutes and is suitable for use in any qPCR thermal cycler with (FAM/HEX) detection. It is a double-target assay, specific for COVID-19 and other coronaviruses related to SARS. The assay kit contains two lyophilized master mixes for virus detection and confirmation, as suggested by international guidelines.

The assay does not show cross reactions with other common human respiratory CoVs or MERS and includes an internal amplification control in each master mix.

Vircell, which has always been concerned and committed to respiratory infectious diseases in China, has now made a tremendous R&D effort to develop this novel product in order to contribute as much as possible to understanding and containing this highly contagious disease.

Related Links:
Vircell

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.